新生儿心脏手术中纤维蛋白原浓缩物与冷沉淀对体外血凝块降解的影响
这项随机试验比较了新生儿心脏手术后使用纤维蛋白原浓缩物与冷沉淀的效果。主要终点是术后24小时体外血凝块降解百分比变化。结果显示研究组术后24小时降解更明显,但术后输血量更少,出血或血栓事件无差异。
要点
- 纤维蛋白原浓缩物组术后24小时血凝块降解更明显。
- 纤维蛋白原浓缩物组术后输血量显著少于冷沉淀组。
- 两组出血或血栓事件无差异。
核心结论
- 新生儿心脏手术后使用纤维蛋白原浓缩物与冷沉淀相比,围术期体外血凝块降解相似,术后24小时降解更快,术后输血更少,出血或血栓并发症无增加。
主要发现
- 出血或血栓事件无差异。
临床怎么用
- 新生儿心脏手术后使用纤维蛋白原浓缩物可有效恢复止血并减少输血,不增加出血或血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neonates undergoing cardiac surgery require fibrinogen replacement to restore hemostasis after cardiopulmonary bypass (CPB). Cryoprecipitate is often the first-line treatment, but recent studies demonstrate that fibrinogen concentrate (RiaSTAP; CSL Behring) may be acceptable in this population. This investigator-initiated, randomized trial compares cryoprecipitate to fibrinogen concentrate in neonates undergoing cardiac surgery ( ClinicalTrials.gov NCT03932240). The primary end point was the percent change in ex vivo clot degradation from baseline at 24 hours after surgery between groups. Secondary outcomes included intraoperative blood transfusions, coagulation factor levels, and adverse events. METHODS: Neonates were randomized to receive cryoprecipitate (control group) or fibrinogen concentrate (study group) as part of a post-CPB transfusion algorithm. Blood samples were drawn at 4 time points: presurgery (T1), after treatment (T2), arrival to the intensive care unit (ICU) (T3), and 24 hours postsurgery (T4). Using the mixed-effect models, we analyzed the percent change in ex vivo clot degradation from a patient's presurgery baseline at each time point. Intraoperative blood product transfusions, coagulation factor levels, perioperative laboratory values, and adverse events were collected. RESULTS: Thirty-six neonates were enrolled (intent to treat [ITT]). Thirteen patients in the control group and seventeen patients in the study group completed the study per protocol (PP). After normalizing to the patient's own baseline (T1), no significant differences were observed in clot degradation at T2 or T3. At T4, patients in the study group had greater degradation when compared to those in the control group (826.5%, 95% confidence interval [CI], 291.1-1361.9 vs -545.9%, 95% CI, -1081.3 to -10.4; P < .001). Study group patients received significantly less median post-CPB transfusions than control group patients (ITT, 27.2 mL/kg [19.0-36.9] vs 41.6 [29.2-52.4]; P = .043; PP 26.7 mL/kg [18.8-32.2] vs 41.2 mL/kg [29.0-51.4]; P < .001). No differences were observed in bleeding or thrombotic events. CONCLUSIONS: Neonates who received fibrinogen concentrate, as compared to cryoprecipitate, have similar perioperative ex vivo clot degradation with faster degradation at 24 hours postsurgery, less post-CPB blood transfusions, and no increased bleeding or thrombotic complications. Our findings suggest that fibrinogen concentrate adequately restores hemostasis and reduces transfusions in neonates after CPB without increased bleeding or thrombosis risk.
引用
- Downey LA, Moiseiwitsch N, Nellenbach K, et al. Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery. Anesth Analg. 2024. PMID: 39116012. doi:10.1213/ANE.0000000000007123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。